U.S., May 30 -- ClinicalTrials.gov registry received information related to the study (NCT07614776) titled 'A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA(R) HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration' on May 22.
Brief Summary: The aim of this trial is to demonstrate similarity in efficacy between ABP 938 8 mg and aflibercept (US) 8 mg by evaluating the change in best corrected visual acuity (BCVA) in participants with neovascular age-related macular degeneration (nAMD)
Study Start Date: June 01
Study Type: INTERVENTIONAL
Condition:
Neovascular Age-related Macular Degeneration
nAMD
Intervention:
DRUG: ABP 938 8 mg
IVT injection
DRUG: Aflibercept (US) 8...